UFT plus leucovorin in advanced hepatobiliary tumors and pancreatic adenocarcinomas.

Abstract

UFT (tegafur and uracil) has been studied extensively in Japan, with documented efficacy in hepatobiliary and pancreatic cancer. In the United States, UFT with or without leucovorin has not undergone phase II testing in these malignancies. Our current trial is designed primarily to assess the efficacy in terms of response rates to UFT with leucovorin in patients with advanced hepatobiliary and pancreatic cancer. Secondary objectives include determining response duration, time to disease progression, overall survival, quality of life, and toxicity.

• Authors: S Mani
• Journal: Oncology (Williston Park, N.Y.) (Oncology (Williston Park)) Vol. 11 Issue 9 Suppl 10 Pg. 124-7 (Sep 1997) ISSN: 0890-9091 [Print] United States
• PMID: 9348584 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study)

Chemical References

• Antidotes
• Drug Combinations
• UFT(R) drug
• Tegafur
• Uracil
• Leucovorin

Topics

• Adenocarcinoma (drug therapy)
• Adult
• Antidotes (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, adverse effects, therapeutic use)
• Cholangiocarcinoma (drug therapy)
• Drug Combinations
• Humans
• Leucovorin (administration & dosage)
• Liver Neoplasms (drug therapy)
• Pancreatic Neoplasms (drug therapy)
• Quality of Life
• Tegafur (administration & dosage)
• Treatment Outcome
• Uracil (administration & dosage)